Comparison of cetuximab to bevacizumab as the first-line bio-chemotherapy for patients with metastatic colorectal cancer: Superior progression-free survival is restricted to patients with measurable tumors and objective tumor response—a retrospective study

Publication | Open Access

DOI Full Paper Access

Citations

References

2014

Year

Yuan-Hao Yang, Jen Kou Lin, Wei Shone Chen, Tzu Chen Lin, Shung-Haur Yang, Jeng-Kai Jiang, Yuan Lan, Chun Chi Lin, Chueh Chuan Yen, Cheng-Hwai Tzeng,

Journal of Cancer Research and Clinical Oncology

First-line Bio-chemotherapyOncologyGastrointestinal OncologyTumor ImmunityColorectal CancerPathologyMetastatic Colorectal CancerSuperior Progression-free SurvivalImmune Checkpoint InhibitorCancer TreatmentMedicineRadiation OncologyMolecular Oncology